← back to search

Patricia A. Spears

University of North Carolina at Chapel Hill · US
Area of research
Oncology · Cancer Research
Research interest
Research interests include Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Cancer survivorship and care, and Economic and Financial Impacts of Cancer.
h-index
37
citations
15,784
works
143
NIH funding
primary concept
Medicine
email

Recent publications

Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial
Nature Medicine 2025cited by 43position: middledoi
Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer
JAMA Oncology 2025cited by 6position: middledoi
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update
Journal of Clinical Oncology 2023cited by 553position: middledoi
Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline
Practical Radiation Oncology 2023cited by 160position: middledoi
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
Archives of Pathology & Laboratory Medicine 2023cited by 84position: middledoi
Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer
JAMA 2022cited by 373position: middledoi
Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches
Frontiers in Oncology 2022cited by 29position: middledoi
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Journal of Clinical Oncology 2021cited by 980position: middledoi
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Journal for ImmunoTherapy of Cancer 2021cited by 79position: middledoi
The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention
Obesity 2021cited by 28position: middledoi
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
npj Breast Cancer 2021cited by 24position: middledoi
Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial
JCO Clinical Cancer Informatics 2020cited by 191position: middledoi
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline
Journal of Clinical Oncology 2019cited by 87position: middledoi
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Journal of Clinical Oncology 2018cited by 2,426position: middledoi
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Archives of Pathology & Laboratory Medicine 2018cited by 1,463position: middledoi
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
Clinical Cancer Research 2018cited by 89position: middledoi
Clinical Development of Novel Drug–Radiotherapy Combinations
Clinical Cancer Research 2018cited by 72position: middledoi
Reply to E.A. Rakha et al
Journal of Clinical Oncology 2015cited by 32position: middledoi
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Journal of Clinical Oncology 2013cited by 4,041position: middledoi
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Archives of Pathology & Laboratory Medicine 2013cited by 1,790position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Kimberly H. Allison · Stanford Medicine8 papers (2013–2023)Lisa M. McShane · National Cancer Institute7 papers (2013–2023)Mitch Dowsett · Breast Cancer Now7 papers (2013–2023)Antonio C. Wolff · Technical University of Denmark7 papers (2013–2023)Patrick L. Fitzgibbons · St. Jude Medical Center5 papers (2013–2018)Wedad Hanna · Sunnybrook Health Science Centre5 papers (2013–2018)Michael F. Press · University of Southern California5 papers (2013–2018)Gail H. Vance · Indiana University School of Medicine5 papers (2013–2018)Giuseppe Viale · European School of Oncology5 papers (2013–2018)John M.S. Bartlett · Edinburgh Cancer Research5 papers (2013–2018)M. Elizabeth Hammond · National Institutes of Health5 papers (2013–2018)Pamela B. Mangu · Intermountain Healthcare5 papers (2013–2018)Michael Bilous · Western Sydney University5 papers (2013–2018)Robert B. Jenkins · Mayo Clinic4 papers (2013–2018)Daniel F. Hayes · Michigan United4 papers (2013–2023)Soonmyung Paik · Yonsei University3 papers (2013–2015)Philip Carr · University of North Carolina at Chapel Hill3 papers (2020–2025)Antonia V. Bennett · University of North Carolina at Chapel Hill3 papers (2020–2025)Claire Snyder · University of Baltimore3 papers (2020–2025)Bryce B. Reeve · Duke University Health System3 papers (2020–2025)